<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920461</url>
  </required_header>
  <id_info>
    <org_study_id>P/2019/423</org_study_id>
    <nct_id>NCT04920461</nct_id>
  </id_info>
  <brief_title>Visual-spatial and Visual-perceptual Disorders Following Cerebellar Strokes</brief_title>
  <acronym>VISUO-CEREBRO</acronym>
  <official_title>Visual-spatial and Visual-perceptual Disorders Following Cerebellar Strokes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at assessing the proportion of patients suffering from neuro-visual troubles&#xD;
      (visual-spatial and/or visual-perceptual ), after cerebellar strokes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Neuro-Visual Disorder</measure>
    <time_frame>Month 3</time_frame>
    <description>Presence of neuro-visual disorder will be confirmed by obtaining at least 2 pathological scores at following neuropsychological tests:&#xD;
Rey &amp; Taylor figures (score from 0 to 36, maximum)&#xD;
Judgment of Line Orientation (score from 0 to 36, maximum)&#xD;
Weschler Adult Intelligence Scale (final score is intelligence quotient, with an average score is fixed at 100)&#xD;
Test of Attentional Performance&#xD;
Visual Object and Space Perception Battery (eight tests each designed to assess a particular aspect of object or space perception, while minimising the involvement of other cognitive skills)&#xD;
Visual agnosia assesment protocole (noted on 10 points)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Cerebellar Lesions</condition>
  <arm_group>
    <arm_group_label>Additional MRI sequences</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Additional MRI sequences</intervention_name>
    <description>Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)</description>
    <arm_group_label>Additional MRI sequences</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological assessment</intervention_name>
    <description>Neurovisual function assessed with neuropsychological tests</description>
    <arm_group_label>Additional MRI sequences</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Being able to pass initial neuropsychological tests within 10 days after stroke&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous central neural system/psychiatric/eye disease (including severe cranial&#xD;
             trauma)&#xD;
&#xD;
          -  Chronic alcoholism&#xD;
&#xD;
          -  MRI contraindication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloi MAGNIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice VOILLY, MD</last_name>
    <phone>0033381668236</phone>
    <email>avoilly@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VOILLY Alice, MD</last_name>
      <email>avoilly@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eloi MAGNIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Perceptual Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

